The decision elaborates on the need to dismiss or stay the case due to the pending of parallel proceedings between affiliated companies and provides a summary of the criteria to be followed in interpreting claims and assessing novelty and inventive steps.

The decision was issued in 12 months and revoked the DexCom patent, dismissing its infringement claim. The decision is now effective in the 17 EU Member States that have ratified the UPC Agreement; it may however be appealed.